Hypertension in adults: the silent killer

Hypertension is a common finding among patients in primary care; ideal pharmacological treatment, however, continues to be debated. What is agreed is that chronic hypertension can cause a wide-range of cardiovascular disease and end-organ damage if left untreated or insufficiently controlled. Management often requires multiple medicines in addition to lifestyle changes to achieve blood pressure targets and reduce overall cardiovascular risk.

**KEY PRACTICE POINTS**

- The line separating blood pressure measurements from being “normotensive” and “hypertensive” is not clear-cut. Consider any elevated readings in the context of a patient’s overall cardiovascular disease (CVD) risk. The balance between these two factors will influence subsequent management decisions.

- Consider using 24-hour ambulatory or at-home monitoring to confirm persistently elevated clinic blood pressure readings, if resources are available.

- Any patient with persistently elevated blood pressure readings should be encouraged to make lifestyle changes, e.g. weight loss, increased exercise, dietary changes including reducing sodium intake, limiting alcohol consumption, smoking cessation. Early adoption of meaningful changes could delay or prevent the need for antihypertensive medicines later in life. However, this may not be achievable for all patients.

- For patients with severe hypertension (e.g. ≥ 160/100 mmHg), antihypertensive treatment should be initiated immediately, in addition to lifestyle changes, regardless of the patient’s CVD risk (although CVD risk should still be calculated).

- For all other patients with a blood pressure persistently ≥ 130/80 mmHg, treatment decisions should be based on their five-year CVD risk calculated using New Zealand primary prevention equations:
  - **CVD < 5%**: antihypertensive treatment is not recommended; proceed with lifestyle changes
  - **CVD 5 – 15%**: consider antihypertensive treatment if blood pressure measurements are ≥ 140/90 mmHg, in addition to lifestyle changes
  - **CVD ≥ 15%**: antihypertensive treatment is recommended, in addition to lifestyle changes

- Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), calcium channel blockers and thiazide/thiazide-like diuretics are all first-line antihypertensives:
  - The choice of antihypertensive and combination of treatment depends on patient co-morbidities (e.g. diabetes, renal impairment) and other characteristics (e.g. pregnancy)
  - Beta-blockers are no longer first-line unless specifically indicated for a co-morbidity

- Initial treatment with two low-dose antihypertensives together (i.e. dual antihypertensive treatment) provides a more significant blood pressure-lowering effect for most patients compared with high dose monotherapy, while also reducing the risk of adverse effects. Initial monotherapy remains appropriate for certain patient groups, e.g. those within 20/10 mmHg of their blood pressure target, committing to major lifestyle changes, elderly (e.g. aged ≥ 80 years) or frail.

- Blood pressure targets should be individualised according to the patient’s CVD risk, co-morbidities and treatment objectives.

- For patients not achieving blood pressure targets despite the use of two antihypertensives, the doses of existing medicines can be increased if they are close to their goal, or a third antihypertensive can be added if not.

- If targets are still not being achieved despite use of three antihypertensives, reassess adherence to medicine and lifestyle changes as well as possible secondary causes, prior to considering the addition of another medicine, e.g. spironolactone or a beta-blocker. N.B. 24-hour ambulatory or at-home monitoring should also be strongly considered at this stage to confirm the patient’s true blood pressure, if not already completed.
Hypertension is a continuum requiring regular review

Hypertension is a common incidental clinical finding in primary care. While transient increases in blood pressure are normal and can occur for a variety of reasons, persistent elevation represents an important modifiable risk factor for many conditions including stroke, myocardial infarction, heart failure, atrial fibrillation, kidney disease and cognitive decline. However, most people with hypertension are asymptomatic, giving rise to the moniker “silent killer” due to its insidious, chronic and progressive nature.

International guidelines vary in the thresholds used to define hypertension. While it has previously been common practice in New Zealand to consider any clinic blood pressure ≥ 140/90 mmHg as being “hypertensive”, blood pressure measurements alone are now considered insufficient to define and guide the management of hypertension in primary care. Blood pressure has a normal distribution across the general population and the cardiovascular disease (CVD) risk associated with increasing measurements is continuous. If additional factors are present that elevate cardiovascular risk further, a patient is more likely to experience a cardiovascular event, even if their blood pressure is within 130 – 139/85 – 89 mmHg, the line between normotension and hypertension is therefore not clear-cut.

Risk factors for hypertension include: age ≥ 65 years, male sex, excess body weight, sedentary lifestyle, diabetes, high LDL-C/triglycerides, sustained increased resting heart rate (> 80 beats/min), a personal or family history of cardiovascular disease or hypertension (genetics), early-onset menopause, smoking (current or past), and psychosocial or socioeconomic factors.

Hypertension is prevalent yet undertreated in New Zealand

The age-standardised mean systolic blood pressure in people in New Zealand is increasing due to a range of factors, including higher rates of obesity and sedentary lifestyles, as well as the increased consumption of foods containing a high content of fat, sugar and salt. Hypertension is often under-treated; Māori, Pacific and Asian peoples with hypertension have significantly lower rates of antihypertensive use compared with European/Other peoples (Figure 1), a trend which has remained consistent over time. While not all patients with hypertension require pharmacological treatment (see: “When to initiate antihypertensive medicines” on page 5), these disparities need to be recognised and addressed across primary care to achieve more equitable health outcomes.

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Prevalence of hypertension</th>
<th>Antihypertensive use</th>
<th>% untreated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>22.5%</td>
<td>16.7%</td>
<td>25.8%</td>
</tr>
<tr>
<td>Māori</td>
<td>23.6%</td>
<td>14.6%</td>
<td>38.1%</td>
</tr>
<tr>
<td>Pacific</td>
<td>28.1%</td>
<td>11.9%</td>
<td>57.7%</td>
</tr>
<tr>
<td>Asian</td>
<td>16.2%</td>
<td>8.6%</td>
<td>46.9%</td>
</tr>
<tr>
<td>European/Other</td>
<td>22.2%</td>
<td>18.1%</td>
<td>18.5%</td>
</tr>
</tbody>
</table>

Figure 1. Prevalence of hypertension versus rates of antihypertensive use in New Zealand by ethnicity. Data obtained from the 2020/21 Ministry of Health New Zealand Health Survey. The percentage of patients not taking an antihypertensive was calculated using the datasets for “Raised blood pressure (measured)” and “High blood pressure (medicated)”. 
Diagnosing hypertension

Treatment for hypertension often involves lifelong exposure to multiple medicines and their potential adverse effects. Therefore, it is essential that hypertension is accurately diagnosed in primary care, but this can be challenging as most patients with hypertension are asymptomatic.

If a patient has a clinic blood pressure measurement ≥ 130/80 mmHg a clinical evaluation should be conducted to:
1. Confirm the elevated blood pressure
2. Assess CVD risk
3. Determine if any end organ damage has occurred
4. Identify any causes of secondary hypertension

1. Confirming elevated blood pressure

To achieve a more accurate assessment, it is recommended that two or more blood pressure measurements are taken, at least two minutes apart. Ideally, an additional measurement should also be taken in the patient’s other arm in case there is a significant difference. Consistent systolic blood pressure differences ≥ 10 mmHg between arms are associated with an increased risk of cardiovascular disease.

If blood pressure measurements are elevated at a single appointment, another reading should ideally be taken at a separate appointment on a different day to confirm a diagnosis of hypertension. N.B. Ensure an appropriate blood pressure cuff size is used.

Consider the need for referral or urgent care if the patient’s blood pressure is ≥ 180/110 mmHg and there are signs of end organ damage (malignant hypertension), e.g. abnormalities on ECG, or if the patient is pregnant. For further information, see: “Investigate for end organ damage and co-morbidities”

Consider an out-of-clinic blood pressure assessment

Even when standardised methods for blood pressure measurement are used, clinic readings do not always reflect true blood pressure due to patient-specific psychological, physiological and behavioural factors. On average, measurements are 5 – 10 mmHg higher in this setting compared with at-home or ambulatory monitoring. Therefore, 24-hour ambulatory monitoring (the “gold standard”) or at-home monitoring should be considered if resources are available to confirm a diagnosis of hypertension and to rule out:

- **White-coat hypertension** if measurements are consistently elevated despite the absence of obvious risk factors
- **Masked hypertension** if clinic blood pressure is consistently normal but there are clinical features consistent with hypertension, e.g. signs of end organ damage

**For further information on 24-hour ambulatory or at-home monitoring, see: “Out-of-clinic blood pressure testing in primary care” at [bpac.org.nz/BPJ/2016/May/blood-pressure.aspx](http://bpac.org.nz/BPJ/2016/May/blood-pressure.aspx)**

2. Perform a CVD risk assessment

CVD risk assessment forms the basis for discussions about prognosis and treatment options with the patient and provides information about other factors affecting cardiovascular management, e.g. diabetes, and the prevention of myocardial infarction and stroke.

A five-year CVD risk assessment should be performed in **all patients with a blood pressure persistently ≥ 130/80 mmHg** (see: “When to initiate antihypertensive medicines” on page 5). In addition, five-year CVD risk assessments are recommended from age **45 years in males** and **55 years in females**. However, it is recommended that assessments should be:

- 10 years earlier for people with personal or family history risk factors for CVD or diabetes
- 15 years earlier for people of Māori, Pacific or South-Asian ethnicity
- 20 years earlier for people with severe mental illness
- From diagnosis for people with type 1 or 2 diabetes

The five-year CVD risk thresholds have been established based on the New Zealand primary prevention equations (derived from the PREDICT study), which incorporate a wider range of variables. Most patient management systems will have an integrated CVD risk assessment tool. Alternatively, an online CVD risk calculator, with the option of using PREDICT data, is available from: [cvdcalculator.com](http://cvdcalculator.com). These tools also provide a pictorial representation of the potential benefits and harms with and without intervention to inform shared decision making with the patient if antihypertensive treatment is ultimately indicated (see: “When to initiate antihypertensive medicines” on page 5).
3. Investigate for end organ damage and co-morbidities

After confirming elevated blood pressure and assessing the patient’s five-year CVD risk, further investigations should include (at a minimum):

- Dipstick urine test for blood or protein
- Quantification of urinary protein, e.g. by assessing albumin:creatinine ratio (ACR)
- Laboratory investigations for electrolytes and creatinine (eGFR), lipids, HbA1c
- An ECG to assess for signs of left ventricular hypertrophy, atrial fibrillation or evidence of historical ischaemic heart disease. Consider referring for an echocardiogram if indicated.

Assess for other symptoms indicative of end organ damage, e.g. chest pain, breathlessness, visual disturbances, transient focal weakness.

Consider ophthalmoscopic examination of the fundus, particularly in patients reporting visual disturbances, as persistently elevated blood pressure can cause retinopathy, choroidopathy and optic neuropathy. Key features include copper (or silver) wiring, arteriovenous nicking and retinal haemorrhages.

For further information on hypertensive retinopathy and example images, see: www.msdmanuals.com/professional/eye-disorders/retinal-disorders/hypertensive-retinopathy

4. Consider secondary causes of hypertension

Most patients diagnosed with hypertension have primary (or essential) hypertension, where there is no clinically identifiable cause. While the pathophysiology of primary hypertension is not fully understood, it is thought to involve a complex interplay of genetic predisposition, environmental factors and age-associated stiffening of blood vessels.

In approximately one in ten patients with hypertension, increased blood pressure measurements are associated with an underlying condition or stressor (secondary hypertension). If these factors can be more effectively managed or resolved, it may prevent unnecessary pharmacological intervention. Secondary causes of hypertension should be suspected in young adults (e.g. aged < 30 years) without a family history of hypertension or other risk factors.

Secondary causes of hypertension include:

- High alcohol intake, e.g. consistently having > 10 standard drinks per week for females or > 15 standard drinks for males
- Illicit drugs, e.g. amphetamine or cocaine use
- Certain medicines, e.g. oral contraceptives and corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), ciclosporin and decongestants, e.g. phenylephrine
- Obstructive sleep apnoea
- Aortic coarctation, suggested by a diminished or delayed femoral pulse and low or unobtainable blood pressure in the legs, or abnormal differences in the upper and lower extremity arterial pulses
- Renovascular or primary renal disease
- Renal parenchymal disease, including glomerulonephritis, suggested by a history of urinary tract infection or obstruction, haematuria, analgesic misuse or a family history of polycystic kidney disease
- Endocrine disorders, e.g. Cushing’s syndrome (excessive cortisol production), Conn’s syndrome (also known as hyperaldosteronism, involving excessive aldosterone production), phaeochromocytoma (a rare adrenal gland tumour), hypo-/hyperthyroidism

The options for managing hypertension

Lifestyle modifications are important for all patients

Healthy lifestyle advice should be given to all patients with persistently elevated blood pressure measurements and reinforced if a diagnosis of hypertension is ultimately made. There is clear evidence from clinical trials that lifestyle changes can reduce mean blood pressure measurements and even prevent hypertension if they are sustained.

Key modifications to make where applicable include:

- Weight loss. Even small losses help reduce blood pressure (systolic blood pressure is estimated to decrease approximately 1 – 2 mmHg/kg lost).

For further information on methods for weight loss, see: bpac.org.nz/2022/weight-loss.aspx

A healthy diet with reduced sodium intake (< 1.5 g/day is optimal but aim for at least a 1 g/day reduction) and optimised potassium intake (3.5 – 5.0 g/day). Other important features include the diet being rich in vegetables, fruit, whole grains, low-dairy and reduced saturated/total fat. International guidelines are increasingly recommending the dietary approaches to stop hypertension (DASH) diet. Smartphone apps, e.g. "FoodSwitch", can help people assess nutritional content of labelled products and identify healthier alternatives.

Increasing physical activity, e.g. regular moderate intensity exercise such as walking for at least 30 minutes per day, five days per week, if possible. However, any increase in exercise engagement is likely beneficial.
Warning: the fixed-dose combination antihypertensive Accuretic (quinapril with hydrochlorothiazide) should no longer be used

Voluntary recalls of the combination antihypertensive Accuretic (quinapril with hydrochlorothiazide) have been occurring worldwide since March, 2022, after the supplier (Pfizer) advised that batches had been contaminated with nitrosamines. Long-term exposure to nitrosamines has been associated with a small cumulative risk of cancer.

PHARMAC has advised that Accuretic will be delisted in early 2023 (N.B. Pfizer has provided no certain timeline as to when a replacement supply without impurities will be available). No new patients should be initiated on Accuretic, and those currently taking it should be switched to an alternative treatment.

Choosing a suitable antihypertensive

All first-line antihypertensives have a comparable blood pressure lowering effect and therefore all are suitable choices for patients without complicating factors or interacting medicines (see: “Consider patient characteristics and co-morbidities” on Page 7).

In New Zealand, funded first-line options include (see Table 1 for dosing recommendations):

- Angiotensin-converting-enzyme (ACE) inhibitors
- Angiotensin-II receptor blockers (ARBs). N.B. Despite previously being regarded as a second-line option after ACE inhibitors, ARBs are now considered to provide comparable benefit for treating patients with hypertension and are often better tolerated.
- Calcium channel blockers
- Thiazide and thiazide-like diuretics

For further information see: “Prescribing ACE inhibitors: time to reconsider old habits” at: bpac.org.nz/2021/ace.aspx
Table 1. Recommended adult dosing for commonly used antihypertensive medicines in New Zealand.\textsuperscript{11} \textbf{N.B.} Lower initial dosing of ACE inhibitors/ARBs (e.g. half the initial dose) and more gradual titration may be required for elderly or frail patients, or in patients with renal impairment, cardiac decompensation, volume depletion or concomitant diuretic use. For further information on dosing recommendations, refer to the New Zealand Formulary: \url{www.nzf.org.nz/nzf_1168}.

<table>
<thead>
<tr>
<th>Class</th>
<th>Funded option as of Jan, 2023</th>
<th>Initial dose (may be lower in some patients)</th>
<th>Dose range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE inhibitors</strong></td>
<td>Enalapril</td>
<td>5 mg, once daily</td>
<td>Usual maintenance dose 20 mg, once daily; maximum 40 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Lisinopril</td>
<td>10 mg, once daily</td>
<td>Usual maintenance dose 20 mg, once daily; maximum 80 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Perindopril</td>
<td>4 mg, once daily in the morning</td>
<td>Maximum 8 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Quinapril</td>
<td>10 mg, once daily</td>
<td>Usual maintenance dose 20 – 40 mg, daily in 1 – 2 divided doses; maximum 80 mg, daily</td>
</tr>
<tr>
<td></td>
<td>Ramipril</td>
<td>2.5 mg, once daily</td>
<td>Maximum 10 mg, daily</td>
</tr>
<tr>
<td><strong>ARBs</strong></td>
<td>Candesartan</td>
<td>8 mg, once daily</td>
<td>Usual maintenance dose 8 mg, once daily; maximum 32 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Losartan</td>
<td>50 mg, once daily</td>
<td>Usual maintenance dose 50 mg, once daily; maximum 100 mg, once daily</td>
</tr>
<tr>
<td><strong>Calcium channel blockers</strong></td>
<td>Amlodipine</td>
<td>5 mg, once daily</td>
<td>Maximum 10 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Diltiazem (modified release)</td>
<td>180 – 240 mg, once daily</td>
<td>Usual maintenance dose 240 – 360 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Felodipine</td>
<td>5 mg, once daily in the morning</td>
<td>Usual maintenance dose 5 – 10 mg, once daily</td>
</tr>
<tr>
<td></td>
<td>Verapamil (immediate release)</td>
<td>80 mg, two or three times daily</td>
<td>Maximum 160 mg, two or three times daily</td>
</tr>
<tr>
<td></td>
<td>Verapamil (modified release)</td>
<td>120 – 240 mg, once daily</td>
<td>Maximum 240 mg, twice daily</td>
</tr>
<tr>
<td><strong>Thiazide and thiazide-like diuretics</strong></td>
<td>Bendroflumethiazide</td>
<td>2.5 mg, once daily in the morning</td>
<td>Maximum doses of 10 mg, daily have been used; however, doses higher than 2.5 mg, daily increase the risk of adverse effects and have a limited additional blood pressure lowering effect</td>
</tr>
<tr>
<td></td>
<td>Chlortalidone</td>
<td>12.5 – 25 mg, once daily in the morning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indapamide</td>
<td>2.5 mg, once daily in the morning</td>
<td></td>
</tr>
<tr>
<td><strong>Fixed-dose combination treatment</strong></td>
<td>Losartan + hydrochlorothiazide</td>
<td>1 tablet (50 mg losartan + 12.5 mg hydrochlorothiazide), once daily</td>
<td>Maximum 2 tablets, once daily</td>
</tr>
</tbody>
</table>

\textsuperscript{*} Cilazapril is another ACE inhibitor that was previously used extensively in New Zealand, however, it is no longer funded for new patients.

\textsuperscript{†} Quinapril with hydrochlorothiazide is another fixed-dose combination treatment that was used in New Zealand, however, it is no longer available due to a stock impurity issue. For further information, see “Warning: the fixed-dose combination antihypertensive Accuretic (quinapril with hydrochlorothiazide) should no longer be used” on Page 5.
Beta-blockers are no longer considered a first-line antihypertensive unless there is a clinical need

Beta-blockers are less effective at reducing stroke risk compared with other antihypertensive medicines and are often poorly tolerated. However, beta-blockers may be preferred early in treatment for patients with some co-morbidities, such as ischaemic heart disease (as they also help to decrease heart rate, increase diastolic filling time, decrease cardiac contractility and reduce myocardial oxygen demand) or atrial fibrillation (as they help to control heart rate).

Consider patient co-morbidities and characteristics

Two-thirds of patients with hypertension have a co-morbidity, which may in turn influence the suitability of the antihypertensive used (Table 2). For example, in patients with hypertension and gout, losartan is often favoured due to its dual blood pressure lowering/uricosuric effects, while thiazide diuretics should be avoided as they promote urate reabsorption in proximal renal tubules.

Other patient characteristics may also affect the choice of antihypertensive. For example, ACE inhibitors or ARBs are sometimes favoured in patients aged under 55 years due to the potential for a more significant reduction in renin levels. However, exposure to ACE inhibitors and ARBs increases the risk of fetal abnormalities when used during pregnancy. Therefore, any females planning or considering pregnancy should ideally use an alternative medicine, or switch from an ACE inhibitor/ARB to another option once the pregnancy

Table 2. Antihypertensive recommendations based on patient co-morbidities and characteristics

<table>
<thead>
<tr>
<th>Co-morbidity or characteristic</th>
<th>Potentially Beneficial</th>
<th>Avoid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic kidney disease</td>
<td>ACE inhibitors or ARBs</td>
<td>High salt intake</td>
</tr>
<tr>
<td></td>
<td>Calcium channel blockers</td>
<td>Thiazides in patients with more than mild renal impairment</td>
</tr>
<tr>
<td></td>
<td>Loop diuretics (if eGFR &lt; 30 mL/min/1.73 m²)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Type 1 – ACE inhibitors or ARBs then thiazide (or thiazide-like) diuretic or calcium channel blocker</td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Type 2 – ACE inhibitors</td>
<td>High dose thiazide diuretics (low doses are acceptable)</td>
</tr>
<tr>
<td>Heart failure or asymptomatic left ventricular dysfunction</td>
<td>Beta-blockers (dose adjustments may be required for patients with renal dysfunction)</td>
<td>Non-dihydropyridine calcium channel blockers (e.g. diltiazem, verapamil)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Beta-blockers in uncontrolled heart failure</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>Beta-blockers without intrinsic sympathomimetic activity, e.g. carvedilol</td>
<td>No specific cautions</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors or ARBs</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Beta-blockers</td>
<td>No specific cautions</td>
</tr>
<tr>
<td></td>
<td>Rate limiting calcium channel blocker, e.g. diltiazem</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors or ARBs</td>
<td></td>
</tr>
<tr>
<td>Angina</td>
<td>Beta-blockers</td>
<td>No specific cautions</td>
</tr>
<tr>
<td></td>
<td>Calcium channel blockers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors or ARBs</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease, i.e. stroke</td>
<td>ACE inhibitors or ARBs</td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Calcium channel blockers</td>
<td>Thiazide diuretics in very elderly patients or those with poor daily fluid intake as they could contribute to hypoperfusion</td>
</tr>
<tr>
<td></td>
<td>Low-dose thiazide diuretics</td>
<td></td>
</tr>
<tr>
<td>Asthma/COPD</td>
<td>No specific recommendations</td>
<td>Beta-blockers, however, low-dose bisoprolol (or metoprolol) can be used if required in patients with asthma/COPD and heart failure</td>
</tr>
<tr>
<td>Gout</td>
<td>Losartan (has a uricosuric effect)</td>
<td>Thiazide diuretics</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Labetalol</td>
<td>ACE inhibitors and ARBs</td>
</tr>
<tr>
<td></td>
<td>Nifedipine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methyldopa</td>
<td></td>
</tr>
</tbody>
</table>
is confirmed. Recommended antihypertensives during pregnancy include labetalol, nifedipine and methyldopa.

N.B. Chronic hypertension before pregnancy is a risk factor for pre-eclampsia and therefore all females planning a pregnancy should ideally have their blood pressure treated and controlled first, if possible.

For further information on hypertension in pregnancy, see: Diagnosis and Treatment of Hypertension and Pre-eclampsia in Pregnancy in Aotearoa New Zealand (2022 update).

**Initial use of two low-dose antihypertensives can be a good starting point for many patients**

The blood pressure lowering effect of any single antihypertensive at its optimal dose has been estimated to be < 10 mmHg on average. Therefore, initial monotherapy is unlikely to be effective in many patients with hypertension (despite previously being standard practice) and multiple medicines are frequently required to achieve treatment targets. As such, international guidelines now recommend a more pragmatic approach to treatment, with initial use of two low-dose antihypertensives together (dual antihypertensive treatment) being indicated in many cases (Figure 2). For further information, see: “A closer look at the evidence supporting initial treatment with two low-dose antihypertensives”, Page 10. While selection may be influenced by patient co-morbidities (Table 2), an **ACE inhibitor or ARB** with a dihydropyridine **calcium channel blocker** such as amlodipine has been demonstrated to be the most effective combination based on evidence from the ACCOMPLISH trial. Single antihypertensive use may still be a suitable starting point for some, e.g. elderly patients or those already close to their blood pressure target.

**Consider individualised blood pressure targets**

Numerous clinical trials have addressed the concept of the “optimal” blood pressure target for patients with hypertension, and there are discrepancies in recommendations between different international guidelines. In 2018, New Zealand Ministry of Health guidelines specified a target clinic blood pressure of < 130/80 mmHg for most people. However, there has been a shift in some international guidelines to instead use individualised blood pressure targets based on the patient’s CVD risk, co-morbidities and treatment objectives (Table 3). There is strong evidence supporting a lower clinic blood pressure target (i.e. < 130/80 mmHg) for patients with a high CVD risk. However, the absolute benefits are likely outweighed by the potential harms in those with a lower CVD risk, and therefore a more conservative target is often more appropriate for this group (i.e. < 140 mmHg).

For further information, see: “Update: European Society of Hypertension (ESH) 2023 guidelines now available on the management of arterial hypertension” for further discussion about blood pressure targets.

**Intensive blood pressure management**

The potential benefit of using a stricter blood pressure target (systolic blood pressure < 120 mmHg) in patients with high CVD risk has been investigated in large multi-centre clinical trials such as SPRINT and ACCORD. These studies have yielded mixed results, and there is debate as to whether any evidence of benefit outweighs the potential harms in real-world populations, particularly when strict eligibility criteria is

---

**Table 3. Recommendations for individualising patient blood pressure targets**

<table>
<thead>
<tr>
<th>CVD Risk Category</th>
<th>Clinic Measurement</th>
<th>24-hour Ambulatory or At-home Measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>“High” CVD risk</strong>, including current atherosclerotic CVD, heart failure, reduced ejection fraction, diabetes, CKD, aged ≥ 65 years, five-year CVD risk of ≥ 15%</td>
<td>&lt; 130/80 mmHg</td>
<td>&lt; 125/80 mmHg</td>
</tr>
<tr>
<td><strong>“Lower” CVD risk</strong> None of the above risk factors</td>
<td>&lt; 140/90 mmHg</td>
<td>&lt; 135/90 mmHg</td>
</tr>
<tr>
<td>Frailty, dementia, limited life expectancy</td>
<td>Discuss treatment goals to guide decision making; targets can be more lenient and antihypertensive doses may need to be reduced or stopped entirely depending on patient-specific factors.</td>
<td></td>
</tr>
</tbody>
</table>
Is the patient one or more of:
- Within 20/10 mmHg of their blood pressure target?
- Elderly (e.g. aged ≥ 80 years)?
- Frail?
- Committing to major lifestyle changes?

No?

Yes to any?

Low-dose monotherapy
e.g. an ACE inhibitor or ARB

Target not achieved?

Target achieved?

Consider increasing dose or trialling another first-line medicine

Target not achieved?

Continue treatment with consistent long-term follow-up (e.g. 3–6 monthly)*

Target achieved?

Add a third antihypertensive
e.g. an ACE inhibitor/ARB + a calcium channel blocker + a thiazide diuretic

Target not achieved?

Consider increasing dose(s) if close to target

Continue three antihypertensives + add spironolactone or other medicine†

Target not achieved?

Consider referral to secondary care

* Blood pressure should be monitored at least every four-to-six weeks during medicine titration until blood pressure targets have been achieved. The frequency of follow-up in the long-term depends on a range of patient-specific factors, e.g. the severity of hypertension in the context of the patient’s overall CVD risk.

† Such as a beta-blocker or an alpha-blocker

Figure 2. A pragmatic approach to antihypertensive treatment for patients with hypertension.⁵

For further discussion on intensive blood pressure management, see “Go low or no? Managing blood pressure in primary care” at: bpac.org.nz/2017/blood-pressure.aspx
A closer look at the evidence supporting initial treatment with two low-dose antihypertensives

Half the standard dose of any first-line antihypertensive still provides approximately 80% of the maximal blood pressure lowering effect. In addition, two low-dose antihypertensives used together are approximately five times more effective at lowering blood pressure than doubling the dose of a single antihypertensive (Figure 3). Given that hypertension is almost always caused by a combination of pathophysiological processes, countering it using medicines with different mechanisms of action is therefore thought to improve treatment efficacy. Safety is sometimes cited as a concern when prescribing two low dose antihypertensives together, however, the risk of adverse effects is often actually greater with a high dose of a single antihypertensive.

**Figure 3.** Two low-dose antihypertensives used together have a greater blood pressure-lowering effect than doubling the dose of one antihypertensive.

* From a standard initial dose to twice the standard initial dose
† Both antihypertensives at the standard initial dose

N.B. An incremental effect of 1.0 indicates that the systolic blood pressure-lowering effect is exactly additive, 0.5 indicates a sub-additive effect (equivalent to 50% of the additive effect). Figure adapted from Wald DS, *et al.*, 2009.
Poor medicine adherence is a significant barrier to achieving targets

Poor adherence to antihypertensive treatment is a common issue for many patients with hypertension and is an indicator of poor prognosis. Reasons for non-adherence are often multi-faceted and can be difficult to address in primary care.

Potential strategies to encourage and improve adherence include:

- Educating patients at the time of the initial prescription about their medicine(s) and how it works; this message should be reinforced at each appointment. In particular, if a decision is made to initially prescribe two low dose antihypertensives together, emphasise why it is important that both are taken consistently, i.e. to maximise blood pressure control while reducing the risk of adverse effects (compared with high dose monotherapy).
- Selecting antihypertensives with once daily dosing
- Reducing polypharmacy, e.g. using a fixed-dose combination, if available
- Using pill boxes, blister packaging or electronic reminders (e.g. smartphone apps)
- If adverse effects are problematic, consider night-time dosing, which can limit the perception of adverse effects. Further benefits for night-time dosing have been suggested, however, the evidence at present is inconsistent (see: “Night-time antihypertensive dosing: does it reduce the risk of CVD events?” on Page 12).

Intensifying treatment over the short-term

Patients starting antihypertensive treatment should initially be reviewed at least every four-to-six weeks to assess the efficacy of their regimen. Shorter review times may be considered for some patients, e.g. every two weeks if the patient’s measurement was significantly elevated at baseline. If a target is not achieved, the next step depends on how well the patient tolerates treatment and how close they are to their objective (Figure 2): If the patient is close to their target blood pressure and the antihypertensive medicine(s) are well tolerated: increase the dose of their existing antihypertensive(s) and re-emphasise the importance of lifestyle changes
- If the patient is not close to their target blood pressure and adherence is not an issue: add an additional antihypertensive and re-emphasise the importance of lifestyle changes, e.g. for patients who started with two low dose antihypertensives such as an ACE inhibitor (or ARB) and a calcium channel blocker, add a thiazide diuretic

Age alone is not a reason to dial back treatment

The risk of falls or orthostatic hypotension are often cited as concerns when considering blood pressure management in elderly patients (e.g. those aged ≥ 80 years), however, there is no reason to withhold antihypertensives in anyone based on age alone. Routine treatment should generally be offered to elderly patients for as long as they wish to take it. It is their “biological age”, rather than their “chronological age”, that may be a reason for avoiding use based on individual treatment goals. Nevertheless, blood pressure management is one of the few interventions that reduces mortality risk in frail, elderly people.

Read the evidence

The 2008 Hypertension in the Very Elderly trial (HYVET) treated patients aged over 80 years with hypertension averaging 173/91 mmHg for an average of 1.8 years with indapamide and perindopril to a blood pressure target less than 150/80 mmHg. Stroke rates were reduced by 30%, heart failure mortality by 64% and all-cause mortality by 21%. Despite this study being published almost 15 years ago, it is one of the few randomised controlled trials that specifically investigates the benefits of blood pressure management in people aged > 80 years (most exclude such patients).

If antihypertensive treatment is initiated in an elderly patient, starting with low-dose monotherapy is generally recommended, and this approach may be more tolerable as gradually reducing blood pressure is less likely to cause adverse effects, e.g. postural hypotension. Close monitoring and more lenient targets are also appropriate, and the treatment intensity should be reduced if there are any concerning emerging features, e.g. cognitive impairment. If an elderly patient is already taking multiple antihypertensives and becomes progressively more frail over time, it may be suitable to reconsider the treatment intensity depending on treatment priorities, e.g. lower doses or de-escalating treatment to monotherapy.
Blood pressure is associated with circadian variability; in many people, blood pressure drops during the night by 10 – 20% (versus daytime measurements), before increasing upon waking in the morning – a phenomenon known as the “morning surge”. People with hypertension who lack this morning surge due to persistently elevated nocturnal measurements (“non-dippers”) are more likely to have end organ damage, and have an increased risk of cardiovascular events.\(^{31}\)

The 2019 Hygia Chronotherapy trial (N = 19,168) demonstrated that night-time antihypertensive dosing was associated with a lower mean systolic blood pressure while sleeping, and reduced the relative risk of primary CVD outcomes by 45% compared with morning administration.\(^{32}\) This corresponded to an absolute risk reduction of 5.4% for night-time versus morning antihypertensive dosing over the median 6.3 years of follow-up.\(^{32}\) Study authors proposed that night-time dosing of antihypertensives enhanced their effects through “circadian rhythm-dependent influences both on their pharmacokinetics and pharmacodynamics as well as on the mechanisms of blood pressure regulation”.\(^{32}\)

While the Hygia trial findings appear promising at first glance, further investigation is required before night-time dosing is routinely recommended in primary care for the sole purpose of greater CVD protection. Since being published, concerns have been raised around the trial design, conduct and the potential mechanism of effect.\(^{33}\) In addition, the question “why would an antihypertensive work better depending on the time of day it is taken once it reaches a steady state?”\(^{†}\) remains unaddressed.\(^{33}\)

In October, 2022, findings released from the prospective multi-centre TIME trial (N = 21,104) indicate that night-time antihypertensive dosing provides no additional protection against myocardial infarction, stroke and vascular death compared with morning dosing over five years.\(^{34}\) No additional harms associated with night-time dosing were reported.\(^{34}\) Therefore, in contrast to the Hygia trial conclusions, these outcomes suggest patients should simply take their antihypertensive medicines at the time of day most convenient for them and which minimises adverse effects.

\* Primary CVD outcomes was defined as a composite endpoint of myocardial infarction, coronary revascularisation, heart failure, ischaemic stroke, haemorrhagic stroke and CVD death.

\(†\) Steady state occurs when rate of drug absorption equals the elimination rate, i.e. the concentration consistently remains within the range expected to achieve a desired treatment effect.
Resistant hypertension

If a patient’s clinic blood pressure remains > 140/90 mmHg after treatment with an ACE inhibitor or an ARB, plus a calcium channel blocker and a thiazide diuretic at their optimal (or maximally tolerated) dose, then their hypertension is considered “resistant.” Patient adherence to treatment and possible secondary causes should be re-examined, and an added emphasis placed on lifestyle changes. In addition, if the patient is taking optimal, or maximum tolerated, doses of antihypertensive medicines, an appropriate specialist opinion is recommended, if this has not been sought already.

Ultimately, an additional antihypertensive medicine may be required. Options to consider include:

- **Spironolactone** – appropriate in combination with another diuretic if serum potassium is ≤ 4.4 mmol/L and eGFR is ≥ 45 mL/min/1.73m². Spironolactone may be particularly beneficial as many patients with resistant hypertension have high aldosterone levels (even if they do not have clinically apparent primary hyperaldosteronism); spironolactone impairs aldosterone binding to mineralocorticoid receptors which limits vascular resistance. N.B. Spironolactone should be introduced cautiously with ongoing monitoring of serum potassium and creatinine.

- **Beta-blocker** – no longer considered a first-line antihypertensive for patients with uncomplicated hypertension but may be useful if indicated for a co-morbidity, e.g. atrial fibrillation. All beta-blockers have comparable blood pressure lowering effects.

- **Alpha-blocker** (e.g. doxazosin) – beneficial for lowering blood pressure but should be used with caution in females as these medicines may sometimes cause urinary stress incontinence and loss of bladder control. A scenario where alpha-blockers may be considered is in males with hypertension who also have benign prostatic hyperplasia to alleviate nocturia.

Novel techniques for treating patients with resistant hypertension

A range of novel procedure- and device-based strategies have been investigated for the management of resistant hypertension. For example, renal sympathetic nerve denervation is a catheter-based technique used to ablate specific portions of renal artery nerves, thereby limiting sympathetic activity and the associated effects on blood pressure. Despite promising results in clinical trials, there is currently insufficient evidence to support routine use of this and other novel treatments in patients with resistant hypertension. Patients who may potentially benefit from such techniques (e.g. those with hypertension resistant to all suitable pharmacological treatment options) should be discussed with a cardiologist.

Longer-term follow-up and monitoring

Once a blood pressure target has been achieved, continued long-term follow-up is important to ensure levels are maintained, and to reinforce the importance of medicine adherence and a healthy lifestyle. Guidelines suggest patients with hypertension should be reviewed three-to-six-monthly. However, less frequent review may be more practical for some patients with stable blood pressure measurements, e.g. annually in otherwise healthy patients who are also committing to lifestyle changes and take their medicines regularly. These appointments also provide an opportunity to monitor electrolytes, renal function and albumin/creatinine ratio, in addition to checking for any emerging signs of end organ disease and associated conditions, e.g. retinopathy, heart failure.

**Acknowledgement:** Thank you to Dr. John Edmond, Consultant Cardiologist, Te Whatu Ora Southern, Senior Clinical Lecturer, Dunedin School of Medicine, University of Otago and Dr. Joan Leighton, General Practitioner, Te Whatu Ora Waitaha Canterbury, for expert review of this article.

N.B. Expert reviewers do not write the articles and are not responsible for the final content. bpacnz retains editorial oversight of all content.
New ESH hypertension guidelines have been released, providing clinicians with further direction when treating patients with hypertension. The 2023 update largely reflects the recommendations established in the previous version of the guideline (2018), but has been expanded based on more recent research, and considers a wider range of conditions and practical concepts, e.g. greater emphasis on out-of-office measurements.

As outlined in the 2018 New Zealand Ministry of Health cardiovascular risk consensus statement, the 2023 ESH guidelines note that antihypertensive prescribing decisions should usually be made in accordance with the patients associated CVD risk, not their blood pressure in isolation (unless it is significantly elevated, e.g. ≥ 160/100 mmHg). These guidelines also endorse the use of two low-dose antihypertensives as a starting point for most patients requiring antihypertensive treatment, with a preference for once daily dosing and single fixed-dose combination pills (if available). While any combination of first-line antihypertensives can be prescribed (except for ACE inhibitors with ARBs), it is recommended that treatment “should be preferentially based on combinations of an ACEi or an ARB with CCB or a thiazide/thiazide-like diuretic”.

The place of beta-blockers in treatment is also revisited. While this medicine class is less effective at preventing stroke compared with first-line antihypertensives, beta-blockers are noted as having other favourable effects across the management of at least 50 conditions that may co-exist with hypertension. Therefore, while their positioning in the antihypertensive hierarchy remains unchanged for patients with uncomplicated hypertension, the 2023 ESH guidelines emphasise that from a practical perspective they should still be considered as a monotherapy or at any stage in combination treatment in patients with relevant co-morbidities, e.g. heart failure, atrial fibrillation.

The 2023 ESH update recommends that a blood pressure target of < 140/80 mmHg is appropriate for most patients “because this accounts for the major portion of the protective effect of BP-lowering”. If antihypertensive treatment is well-tolerated, the systolic blood pressure objective can be further reduced to < 130 mmHg in most patients aged < 80 years (ideal range 120–129/70–79 mmHg). Lowering the diastolic target threshold from < 90 mmHg (suggested in 2018 ESH guidelines) to < 80 mmHg was justified based on the incremental reduction in CVD outcomes and mortality observed in RCTs. Intensive blood pressure management (i.e. targeting blood pressure < 120/70 mmHg) continues to be recommended against, mainly because any small protective effect demonstrated in clinical trials is outweighed by the increased risk of harm and discontinuation in the general population.

The information in this update box represents a summary of selected content. To review the full guidelines, including management recommendations for specific demographics and clinical conditions, see: Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023;Publish Ahead of Print. doi:10.1097/HJH.0000000000003480
References


